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Themetazoanmitochondrial translationmachinery is
unusual in having a single tRNAMet that fulfills the dual
roleof the initiator andelongator tRNAMet. Aportionof
the Met-tRNAMet pool is formylated by mitochondrial
methionyl-tRNA formyltransferase (MTFMT) to gen-
erate N-formylmethionine-tRNAMet (fMet-tRNAmet),
which is used for translation initiation; however, the
requirement of formylation for initiation in human
mitochondria is still under debate. Using targeted
sequencing of the mtDNA and nuclear exons encod-
ing the mitochondrial proteome (MitoExome), we
identified compound heterozygous mutations in
MTFMT in two unrelated children presenting with
Leigh syndrome and combined OXPHOS deficiency.
Patient fibroblasts exhibit severe defects in mito-
chondrial translation that can be rescued by exoge-
nous expression of MTFMT. Furthermore, patient
fibroblasts have dramatically reduced fMet-tRNAMet
levels and an abnormal formylation profile of mito-
chondrially translated COX1. Our findings demon-
strate that MTFMT is critical for efficient human
mitochondrial translation and reveal a human
disorder of Met-tRNAMet formylation.428 Cell Metabolism 14, 428–434, September 7, 2011 ª2011 ElsevieINTRODUCTION
Of the90 protein components of the oxidative phosphorylation
(OXPHOS)machinery, 13 are encoded by themitochondrial DNA
(mtDNA) and translated within the organelle. Defects in mito-
chondrial protein synthesis lead to combined OXPHOS defi-
ciency. Although the mtDNA encodes the ribosomal and transfer
RNAs, all remaining components of the mitochondrial transla-
tional machinery are encoded by nuclear genes and imported
into the organelle. To date, mutations in more than ten different
nuclear genes have been shown to cause defective mitochon-
drial translation in humans. However, molecular diagnosis by
sequencing these candidates in patients with defects in mito-
chondrial translation is far from perfect (Kemp et al., 2011),
underscoring the need to identify additional pathogenic muta-
tions underlying these disorders.
Translation within metazoan mitochondria is reminiscent of
the bacterial pathway, initiating with N-formylmethionine (fMet)
(Kozak, 1983). Unlike bacteria, which encode distinct tRNAMet
molecules for translation initiation and elongation, metazoan
mitochondria express a single tRNAMet that fulfills both roles
(Anderson et al., 1981). After aminoacylation of tRNAMet,
a portion of Met-tRNAMet is formylated by mitochondrial
methionyl-tRNA formyltransferase (MTFMT) to generate fMet-
tRNAMet. The mitochondrial translation initiation factor (IF2mt)
has high affinity for fMet-tRNAMet, which is recruited to the ribo-
somal P site to initiate translation (Spencer and Spremulli, 2004).r Inc.
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Figure 1. Combined OXPHOS Deficiency Due to a Defect in Mito-
chondrial Translation
(A) Biochemical analysis of OXPHOS complexes relative to citrate synthase
(CS) in fibroblasts (Fb), muscle (M), or liver (L), expressed as a percent of mean
from healthy controls.
(B) SDS-PAGE analysis of 35S-methionine-labeled mtDNA-encoded proteins
from control and patient fibroblasts. MtDNA-encoded subunits of complex I
(ND1, ND2, ND3, ND5, ND4L), complex III (cytb), complex IV (COX1, COX2,
COX3), and complex V (ATP6, ATP8) are shown.
(C) The gel in (B) was immunoblotted with antibodies against mtDNA-encoded
ND1, COX1, COX2 and nuclear-encoded SDHA (complex II; loading control).
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MTFMT Mutations Impair Mitochondrial TranslationIn contrast, the mitochondrial elongation factor (EF-Tumt) specif-
ically recruits Met-tRNAMet to the ribosomal A site to participate
in polypeptide elongation. Synthesized proteins can then be
deformylated by a mitochondrial peptide deformylase (PDF)
and demethionylated by a mitochondrial methionyl aminopepti-
dase (MAP1D) (Serero et al., 2003; Walker et al., 2009).Cell MeHere, we applied targeted exome sequencing to two unrelated
patients with Leigh syndrome and combined OXPHOS defi-
ciency to discover pathogenic mutations inMTFMT. Fibroblasts
from these patients have impaired Met-tRNAMet formylation,
peptide formylation, and mitochondrial translation. Despite
studies in yeast suggesting that MTFMT is not essential for
mitochondrial translation (Hughes et al., 2000; Li et al., 2000;
Vial et al., 2003), we show that in humans this gene is required
for efficient mitochondrial translation and function.RESULTS
Mitochondrial Translation Is Impaired in Two Unrelated
Patients with Leigh Syndrome
We studied two unrelated patients with Leigh syndrome and
combined OXPHOS deficiency (Figure 1A). Clinical summaries
for patient 1 (P1) and patient 2 (P2) are provided in the Supple-
mental Results (available online). Patient fibroblasts had reduced
synthesis of most mtDNA-encoded proteins as assayed by
[35S]-methionine labeling in the presence of inhibitors of cyto-
solic translation (Figure 1B). This correlated with reduced steady
state protein levels as detected by immunoblotting (Figure 1C),
and, at least for ND1, was not due to reduced mRNA (Figure S1).
Collectively, these data suggest a defect in translation of
mtDNA-encoded proteins.MitoExome Sequencing Identifies MTFMT Mutations
To elucidate the molecular basis of disease in P1 and P2, we
performed next-generation sequencing of coding exons from
1034 nuclear-encoded mitochondrial-associated genes and
the mtDNA (collectively termed the ‘‘MitoExome’’). DNA was
captured via an in-solution hybridization method (Gnirke et al.,
2009) and sequenced on an Illumina GA-II platform (Bentley
et al., 2008). Details are provided in the Supplemental Results
and Table S1.
We identified 700 single-nucleotide variants (SNVs) and
short insertion or deletion variants (indels) in each patient relative
to the reference genome, and prioritized those that may underlie
a severe, recessive disease (Figure 2A). We first filtered out likely
benign variants present at a frequency of >0.005 in public data-
bases which left20 variants in each patient. We then prioritized
variants that were predicted to have a deleterious impact on
protein function (Calvo et al., 2010), leaving 12 variants.
Focusing on genes that fit autosomal recessive inheritance,
having either homozygous variants or two different variants in
the same gene, only one candidate gene, MTFMT, remained in
each patient (Figure 2A).
We identified three distinct heterozygous variants in our
patients (Figure 2B). Both patients harbor a c.626C / T
mutation. The c.626C site is 20 bp upstream of the 30 end of
exon 4 and is predicted to eliminate two overlapping exonic
splicing enhancers (GTCAAG, TCAAGA) (Fairbrother et al.,
2002) and to generate an exonic splicing suppressor (GTTGTT)
(Wang et al., 2004). Skipping of exon 4 results in a frameshift
and premature stop codon (p.R181SfsX5). The second mutation
in P1 is a nonsense mutation (c.382C/ T, p.R128X), while the
second mutation in P2 changes a highly conserved serine to
leucine in the catalytic core of MTFMT (c.374C/ T, p.S125L)tabolism 14, 428–434, September 7, 2011 ª2011 Elsevier Inc. 429
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Figure 2. Identification of Pathogenic Compound Heterozygous
Mutations in MTFMT
(A) Number of MitoExome variants that pass prioritization filters.
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430 Cell Metabolism 14, 428–434, September 7, 2011 ª2011 Elsevie(Figure S2). An affected cousin of P1 also carries the c.382C/ T
and c.626C/ T mutations.
As predicted by in silico analysis, the shared c.626C / T
mutation caused skipping of exon 4 (Figure 2C). qRT-PCR
analysis revealed that P1 had only 9% full-length MTFMT tran-
script compared to controls (Figure S2), the majority of which
carries the c.382C / T nonsense mutation and lacks the
c.626C / T splicing mutation (Figure 2C). P2 had 56% full-
length MTFMT transcript (Figure S2), all of which appears to
carry the c.374C / T mutation and to lack the c.626C / T
splicing mutation (Figure 2C). Collectively, these results confirm
compound heterozygosity of the MTFMT mutations and almost
complete exon skipping due to the c.626C/ T mutation.
Mitochondrial Translation Is Rescued in Patient
Fibroblasts by Exogenous MTFMT
We used complementary DNA (cDNA) complementation to
prove that the translation defect in these patients is due to muta-
tions inMTFMT. Fibroblasts from both patients showed reduced
levels of the mtDNA-encoded complex IV subunit, COX2,
consistent with a defect in mitochondrial translation, and of the
nuclear-encoded complex I subunit, NDUFB8, reflecting insta-
bility of complex I in the absence of mtDNA-encoded proteins
(Figure 2D). Lentiviral transduction of MTFMT cDNA caused
a significant increase of COX2 andNDUFB8 in both patients (Fig-
ure 2E). In contrast, lentiviral transduction of a control cDNA,
C8orf38, caused no change of these subunits (Figure 2E). These
data confirm that an MTFMT defect is responsible for the
combined OXPHOS deficiency in these patients.
Mitochondrial tRNAMet Pools Are Abnormal in Patient
Fibroblasts
To directly analyze the mitochondrial tRNAMet pools (Figure 3A),
we used a modified protocol of acid-urea PAGE followed by
northern blotting (Enrı´quez and Attardi, 1996; Ko¨hrer and
RajBhandary, 2008; Varshney et al., 1991) (Figure 3B). We
were able to separate the mitochondrial uncharged tRNAMet,(B) Schematic diagram ofMTFMT showing the location of mutations in P1 and
P2 (red bars), exon skipping (gray boxes), and primers for RT-PCR (forward
and reverse arrows).
(C) Electrophoresis of RT-PCR products demonstrates a smaller cDNA
species (280 bp) in P1 and P2 that is particularly prominent in cells grown in
the presence of cycloheximide (+CHX). Top: Sequence chromatograms of
full-length MTFMT RT-PCR products (–CHX) to confirm compound heterozy-
gosity. Bottom: Sequence chromatograms of the smaller RT-PCR products
(+CHX) shows patient cDNA lacks the c.382C/ T (P1) or c.374C/ T (P2)
mutations and skips exon 4, which carries the shared c.626C/ T mutation.
(D and E) Patient and control fibroblasts were transduced with MTFMT cDNA
or control C8orf38 cDNA.
(D) Representative SDS-PAGE western blot shows reduced COX2 and
NDUFB8 in patient fibroblasts and restoration of protein levels withMTFMT but
not C8orf38 transduction. The 70kDa complex II subunit acts as a loading
control.
(E) Protein expression was quantified by densitometry and bar charts show the
level of complex I (NDUFB8) or complex IV (COX2) relative to complex II
(70 kDa) normalized to control, before and after transduction. Error bars show
the mean of three biological replicates and error bars indicate ± 1 standard
error of the mean (SEM). Asterisks indicate p < 0.05 (*), p < 0.01 (**), and
p < 0.001 (***).
See also Figure S2 and Table S1.
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Figure 3. Patient Fibroblasts Have aDefect inMet-tRNAMet Formyla-
tion
(A) In metazoan mitochondria, a single tRNAMet species acts as both initiator
and elongator tRNAMet. After aminoacylation of tRNAMet by the mitochondrial
methionyl-tRNA synthetase (MetRSmt), a portion of Met-tRNA
Met is formylated
by MTFMT to generate fMet-tRNAMet. fMet-tRNAMet is used by the mito-
chondrial IF2 (IF2mt) to initiate translation, whereas Met-tRNA
Met is recognized
by themitochondrial EF-Tu (EF-Tumt) for the elongation of translation products.
(B) Total RNA from control (lanes 5–7) and patient fibroblasts (P1, lanes 8–10;
P2, lanes 11–13) was separated by acid-urea PAGE. Total RNA from MCH58
cells is shown as a reference (lanes 1–4). The mitochondrial tRNAMet (top) and
the cytoplasmic initiator tRNAi
Met (bottom) were detected by northern
hybridization. Total RNA was isolated under acidic conditions, which
preserves both the Met-tRNAMet and fMet-tRNAMet (ac); tRNAs were treated
with copper sulfate (Cu2+), which specifically deacylates Met-tRNAMet but not
fMet-tRNAMet, or with base (OH), which deacylates both Met-tRNAMet and
fMet-tRNAMet. Base-treated tRNAwas reaminoacylated in vitro withMet using
MetRS generating a Met-tRNAMet standard (M).
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fibroblasts and to show that two independent wild-type cell lines
contained uncharged tRNAMet and fMet-tRNAMet, but very little
Met-tRNAMet (Figure 3B, lanes 1–7). In striking contrast, fibro-
blasts from P1 and P2 lacked detectable fMet-tRNAMet and con-
tained mostly Met-tRNAMet along with traces of the unchargedCell MetRNAMet (Figure 3B, compare lanes 8–13 to control lanes 5–7).
We also observed a 2.7-fold increase of the overall mitochondrial
tRNAMet signal in patient fibroblasts compared to control (Fig-
ure 3B, top panel; compare lanes 8 and 11 to control lane 5),
while the cytoplasmic initiator tRNAi
Met showed constant signal
throughout (Figure 3B, bottom panel). The analysis of the mito-
chondrial tRNAMet pools clearly shows a defect in tRNAMet
formylation.
COX1 Protein Formylation Is Decreased in Patient
Fibroblasts
Although fibroblasts from P1 and P2 have severely impaired
mitochondrial translation, they do retain residual activity (Fig-
ure 1B). This residual activity could be due to (1) low activity of
mutant MTFMT generating a small amount of fMet-tRNAMet
that is rapidly consumed in translation initiation and, therefore,
undetectable by Northern blot analyses and/or (2) the human
IF2mt recognizing, albeit weakly, the nonformylatedMet-tRNA
Met
species to support translation initiation. Translation through the
first mechanism would produce formylated protein, while trans-
lation through the second mechanism would produce unformy-
lated protein.
To investigate these two possibilities, we used semiquantita-
tive mass spectrometric analysis to simultaneously measure
three possible N-terminal states of mitochondrially translated
COX1: formylated (Figure 4A), unformylated (Figure 4B), and de-
methionylated (des-Met) (Figure 4C). We applied this method to
complex IV immunoprecipitated from fibroblasts from P1 and
P2 and two independent wild-type cell lines (Figure 4D). Although
no fMet-tRNAMet was detected in patient fibroblasts by northern
blotting (Figure 3B), the dominant COX1 peptide in all four
samples is the formylated species as estimated from total ion
current of each form (Figure 4E). The expression of mitochondrial
PDF and MAP1D was normal in patient fibroblasts (Figure S3).
These semiquantitative analyses clearly demonstrate that patient
fibroblasts retain residual MTFMT activity.
DISCUSSION
Here, we report human patients with mutations in MTFMT, a
gene that has not been previously linked to human disease.
We verified the causal mutations by rescuing the mitochondrial
translation defects in patient fibroblasts via lentiviral transduc-
tion of MTFMT. Analysis of the tRNAMet pools in patient fibro-
blasts revealed severe MTFMT dysfunction. To our knowledge,
the humanmitochondrial tRNAMet profile has not been previously
reported. It is interesting to note that control fibroblasts lack
detectable Met-tRNAMet, suggesting that it is utilized as quickly
as it is produced; either converted to fMet-tRNAMet or used to
donate Met to the growing polypeptide chain. Strikingly, patient
fibroblasts lack detectable levels of fMet-tRNAMet and contain
mostly Met-tRNAMet.
Drastically decreased fMet-tRNAMet levels prevent efficient
mitochondrial translation as demonstrated by the reduced trans-
lation observed in patient fibroblasts. Although fibroblasts from
P1 and P2 have severely impaired mitochondrial translation,
they do retain some residual activity. To understand the origin
of this activity, we measured the relative distribution of three
possible N-terminal states of mitochondrially translated COX1tabolism 14, 428–434, September 7, 2011 ª2011 Elsevier Inc. 431
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Figure 4. Analysis of the COX1 N Terminus in Patient Fibroblasts
(A–C) Annotated MS/MS spectra confirming correct targeting of the three
possibleN termini ofCOX1. The sequenceof thepeptide isMFADRWLFSTNHK
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432 Cell Metabolism 14, 428–434, September 7, 2011 ª2011 Elsevieby mass spectrometry. While previous studies have interrogated
the formylation status of the N terminus of COX1 (Escobar-
Alvarez et al., 2010), our study interrogates all three modification
states and demonstrates mitochondrial methionine excision
activity, which is detectable albeit weak.
Formylated COX1 is the dominant species in patient fibro-
blasts, indicating residual MTFMT activity. Assuming P1’s
nonsense mutation has a full loss of function, then the allele
harboring the shared c.626C/ T mutation must confer MTFMT
activity. Transcript that has not undergone skipping of exon 4
encodes an MTFMT variant harboring a p.S209L missense
mutation. Residue p.S209 is moderately conserved and lies on
the periphery of MTFMT based on homology with the bacterial
enzyme. Similarly, P2’s residual MTFMT activity must originate
from enzyme variants carrying the p.S209L mutation and/or
the p.S125L mutation located in the active site.
Studies in bacteria and yeast have raised questions about
the absolute requirement for Met-tRNAMet formylation. Formyla-
tion is not essential in all bacteria (Newton et al., 1999) and in
yeast disruption of FMT1 causes no discernible defect in mito-
chondrial protein synthesis or function (Hughes et al., 2000;
Li et al., 2000; Vial et al., 2003). Additionally, bovine IF2mt
is able to restore respiration in a yeast mutant lacking both
IF2mt and FMT1 (Tibbetts et al., 2003), suggesting that bovine
IF2mt, like yeast IF2mt, can initiate protein synthesis without
fMet-tRNAMet. However, a number of studies in mammals indi-
cate that formylation of mitochondrial Met-tRNAMet is required
for translation initiation. Bovine IF2mt has a 25- to 50-fold greater
affinity for fMet-tRNAMet than for Met-tRNAMet in vitro (Spencer
and Spremulli, 2004) and 12 of the 13 bovine mtDNA-encoded
proteins retain fMet at the N terminus (Walker et al., 2009).
What are the factors that could allow nonformylated Met-
tRNAMet to initiate mitochondrial translation? In Salmonella
typhimurium, amplification of initiator tRNA genes compensates
for a lack of methionyl-tRNA formyltransferase activity and
allows translation initiation without formylation of the initiator
tRNA (Nilsson et al., 2006). The ‘‘upregulation’’ of the mitochon-
drial tRNAMet in patient fibroblasts (Figure 3B) could, in principle,
be a compensatory response due to limited fMet-tRNAMet.
In summary, we have used MitoExome sequencing to identify
MTFMT as a gene underpinning combined OXPHOS deficiency
associated with Leigh syndrome. We have shown that patient
fibroblasts have a striking deficiency of fMet-tRNAMet leading
to impaired mitochondrial translation. Despite studies in yeast
suggesting that MTFMT is not essential for mitochondrial trans-
lation (Hughes et al., 2000; Li et al., 2000; Vial et al., 2003), we
show here that in humans this gene is required for efficient mito-
chondrial translation and function. More generally, this study
demonstrates how MitoExome sequencing can reveal insightswhere the Met residue may be (A) formylated, (B) unformylated, or (C) absent
(des-Met). Insets show high-resolution, high-mass accuracy precursors from
which the fragmentation spectra were derived. Given their sequence similarity,
peptides are expected to have similar ionization efficiencies.
(D) Extracted ion chromatograms (XICs) of three N-terminal states of COX1
([fMet,Met,des-Met]FADRWLFSTNHK), normalized to an internal COX1 pep-
tide (VFSWLATLHGSNMK).
(E) Fractional ion current of the three N-terminal states of COX1 from immu-
noprecipitated complex IV of patients and controls.
See also Figure S3.
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disease.
EXPERIMENTAL PROCEDURES
Cell Culture
Cells were grown at 37C and 5%CO2 in Dulbecco’smodified Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine
serum (FBS, Invitrogen).
Biochemical Analysis
Spectrophotometric analysis of mitochondrial OXPHOS activity was per-
formed as described previously (Kirby et al., 1999). Investigations were per-
formed with informed consent and in compliance with ethics approval by the
Human Research Ethics Committee of the Royal Children’s Hospital,
Melbourne.
Translation Assays
MtDNA-encoded proteins in patient fibroblasts were labeled with 35S-methio-
nine/35S-cysteine (EXPRE35S35S Protein Labeling Mix; Perkin Elmer Life
Sciences) prior to mitochondrial isolation and analysis of translation products
by SDS-PAGE as previously described (McKenzie et al., 2009).
SDS-PAGE and Immunoblotting
Immunoblotting was performed as previously described (Calvo et al., 2010).
Proteins were detected with the following antibodies: complex II a-70 kDa
subunit monoclonal antibody (MitoSciences, MS204), ND1 polyclonal anti-
body (kind gift from Anne Lombes, Paris), a-complex IV subunit I monoclonal
antibody (Invitrogen, 459600), a-complex IV subunit II monoclonal antibody
(Invitrogen, A6404), Total OXPHOS Human WB Antibody Cocktail containing
aNDUFB8 and aCOX2 (MitoSciences, MS601), and either a-mouse or a-rabbit
IgG horseradish peroxidase (HRP; DakoCytomation).
MitoExome Sequencing
We used an in-solution hybridization capture method (Gnirke et al., 2009) to
isolate target DNA, which was sequenced on the Illumina GA-II platform
(Bentley et al., 2008). The 4.1 Mb of targeted DNA included the 16 kb mtDNA
and all coding and untranslated exons of 1381 nuclear genes, including 1013
mitochondrial genes from the MitoCarta database (Pagliarini et al., 2008), 21
genes with recent strong evidence of mitochondrial association, and 347
additional genes. All analyses were restricted to the mtDNA and coding exons
of the 1034 genes with confident evidence of mitochondrial association
(1.4 Mb). Detailed methods for target selection, sequencing, alignment and
variant detection are submitted elsewhere (S.E.C., unpublished data).
Variant Prioritization
Differences in DNA sequence between each individual and the GRCh37
human reference assembly were identified. Nuclear variants that passed
quality control metrics were prioritized according to three criteria: (1) SNV allele
frequency <0.005 in public databases (dbSNP [Sherry et al., 2001] version 132
and the 1000 genomes project [Durbin et al., 2010] released November 2010)
or indels absent in the 1000 genomes data, (2) variants predicted to modify
protein function as previously described (Calvo et al., 2010), and (3) variants
consistent with recessive inheritance (homozygous variants or two heterozy-
gous variants in the same gene). We also prioritized mtDNA variants annotated
as pathogenic in MITOMAP (Ruiz-Pesini et al., 2007). Detailed methods are
submitted elsewhere (S.E.C., unpublished data).
Sanger DNA Sequencing
DNA isolation, RNA isolation, cDNA synthesis, inhibition of nonsensemediated
decay, and sequencing of PCR products were performed as described
previously (Calvo et al., 2010).
Lentiviral Transduction
The MTFMT open reading frame (ORF) was purchased in a pCMV-SPORT6
vector (Clone ID: BC033687.1, Open Biosystems) and was cloned into the
4-hydroxytamoxifen-inducible lentiviral vector, pF_5x_UAS_MCS_SV40_
puroGEV16-W (Yeap et al., 2010).Cell MeMTFMT viral particles were generated and patient fibroblasts were trans-
duced as described previously (Calvo et al., 2010). Three independent trans-
ductions were performed and cells were harvested after 10–12 days selection
with 1 mg/ml puromycin.
Acid-Urea PAGE and Northern Blotting
Total RNA was isolated from frozen cells under acidic conditions with TRIzol
(Invitrogen) according to the manufacturer’s instructions. Acid-washed glass
beads (0.5 mm diameter; Sigma) were added during extraction. Total RNAs
were separated by acid-urea PAGE as described previously (Enrı´quez and
Attardi, 1996; Ko¨hrer and RajBhandary, 2008; Varshney et al., 1991) with
modifications. In brief, 0.1 A260 units of each RNA sample were loaded onto
a 6.5% polyacrylamide gel containing 7 M urea and 0.2 M sodium acetate
(pH 5.0). Individual tRNAs were detected by northern blotting (Ko¨hrer and
RajBhandary, 2008) with the following hybridization probes: 50TAGTACGG
GAAGGGTATAA30 (mitochondrial tRNAMet) and 50TTCCACTGCACCACT
CTGCT30 (cytoplasmic initiator tRNAi
Met). Northern blots were quantified by
PhosphorImager analysis with ImageQuant software (Molecular Dynamics).
Experiments were performed in duplicate.
Aminoacyl-tRNAs and formylaminoacyl-tRNAs were deacylated by base
treatment in 0.1 M Tris-HCl (pH 9.5) at 65C for 5 min, followed by incubation
at 37C for 1 hr. Aminoacyl-tRNAs were selectively deacylated by treatment
with copper sulfate as described (Schofield and Zamecnik, 1968). Total RNA
was aminoacylated in vitro with methionine using E. coli MetRS as previously
described with minor modifications (Ko¨hrer and RajBhandary, 2008).
Mass Spectrometric Analysis of COX1 N Termini
In brief, complex IV was immunoprecipitated from control and patient fibro-
blasts with MitoSciences’ complex IV Immunocapture kit (MS-401) and sepa-
rated by gel electrophoresis on a NuPAGE 4%–12% Bis-Tris gel (Invitrogen).
A band corresponding to the MW of COX1 was excised and subjected to
in-gel Lys-C digestion (Kinter and Sherman). Extracted peptides were sepa-
rated on C18 column with a 1200-Series nano-LC pump (Agilent) and run on
a LTQ-Velos-Orbitrap mass spectrometer (ThermoFisher) set to scan and to
targeted MS/MS for m/zs corresponding to the z = 3 states of the unformy-
lated, formylated and des-Met species of the N-terminal peptide of COX1
(MFADRWLFSTNHK).
Extracted ion chromatographs (XICs) were generated from the Orbitrap
survey scans based on the z = 3 states of the unformylated, formylated
and des-Met species of the N-terminal peptide of COX1 using XCalibur soft-
ware (ThermoFisher Scientific). The identities of the peaks corresponding to
these species were verified with the accompanying static MS/MS spectra
(Figures 4A–4C). The areas under these peaks were integrated with the
Genesis peak detection algorithm included in XCalibur with all standard
defaults. Peak areas were further normalized to the peak area of a distal
peptide of COX1 (VFSWLATLHGSNMK, m/z 795.9085, z = 2) to ensure that
comparisons allowed for the different amounts of COX1 in control and patient
samples. Full methods are in the Supplemental Experimental Procedures.
Statistical Analysis
Two-way repeated-measures analysis of variance (ANOVA) was used for com-
parisons of groups followed by post hoc analysis via the Bonferroni method.
ACCESSION NUMBERS
The GenBank accession number for the MTFMT sequence reported in this
paper is NM_139242.3.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results, Supplemental
Experimental Procedures, three figures, and one table and can be found
with this article online at doi:10.1016/j.cmet.2011.07.010.
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